Endologix Provides Update On Nellix PMA Process 

IRVINE, Calif., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the U.S Food and Drug Administration (FDA) has requested the Company provide 2-year patient follow-up data from the EVAS-FORWARD IDE Study of the Nellix® EndoVascular Aneurysm Sealing System (Nellix EVAS System).  The Company expects these data to be available and submitted to the FDA in the second quarter of 2017, followed by a possible FDA advisory panel meeting by the end of 2017, and potential FDA PMA approval of Nellix in the second quarter of 2018.

John McDermott, Chief Executive Officer of Endologix, said, "We're disappointed by these requirements and the resulting delay, but encouraged by the 2-year clinical outcomes we have seen so far with Nellix under our newly revised instructions for use.  We remain committed to EVAS with Nellix and have demonstrated outstanding clinical results in selected patients with both traditional and complex AAA anatomies.  We look forward to providing this important new technology to physicians and patients in the U.S. and other markets as soon as possible." 

Nellix is an investigational device in the United States.

The company will discuss the updated Nellix PMA process as part of its business overview at its 2016 Investor Meeting, which is scheduled for Thursday, November 17, 2016. The Investor Meeting will be held on November 17, 2016 from 4:30 to 7:00 pm ET at the Sheraton New York Times Square Hotel in New York City. The event will include a Company update along with presentations from prominent physicians on the Company's product portfolio and a question and answer session with the physicians and Endologix management.
Event:     Endologix Investor Meeting
Date:     November 17, 2016
Time:      4:30 to 7:00 pm ET (registration and refreshments begin at 4:30 pm ET; formal presentation begins at 5:00 pm ET)
Location:      Sheraton New York Times Square Hotel
      811 7 th Ave 53 rd Street, New York, NY

If you liked this article you might like

Endologix Poised for a Potentially Volatile Breakout

5 Stocks Trending Close to Major Breakouts

5 Stocks Set for Explosive Breakouts

These 5 Stocks Under $10 Could Make You a Lot of Money

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains